Atyr Pharma Inc. is a clinical-stage biotechnology company focused on discovering and developing first-in-class medicines derived from its proprietary tRNA synthetase platform. The company translates tRNA synthetase biology into therapies targeting fibrosis and inflammation, addressing unmet needs in rare immune-mediated disorders. Its lead product candidate, efzofitimod, is a selective modulator of neuropilin-2 (NRP2) currently in Phase 3 clinical trials for pulmonary sarcoidosis and Phase 2 trials for systemic sclerosis-related interstitial lung disease and other interstitial lung diseases, including chronic hypersensitivity pneumonitis and connective tissue disease-related ILD. Atyr Pharma Inc. also advances earlier-stage candidates like ATYR0101, a fusion protein from aspartyl-tRNA synthetase for fibrosis, and ATYR0750, a domain of alanyl-tRNA synthetase for liver disorders. Operating in the biopharmaceutical sector, the company emphasizes innovative immunomodulatory approaches to downregulate immune responses in fibrotic conditions. Founded in 2005 and headquartered in San Diego, California, Atyr Pharma Inc. plays a role in advancing treatments for severe pulmonary and inflammatory diseases.